Arvinas ARVN

HealthcareMarket cap $3B2 connections

Arvinas pioneered PROTAC (proteolysis-targeting chimera) protein degraders, creating a new modality of cancer treatment. Its ARV-471 targets the estrogen receptor in breast cancer - degrading the protein rather than blocking it. PROTACs can overcome resistance mutations that defeat standard hormone therapies. Pfizer partnered for $650M+.

Explore Arvinas on the interactive map Relationship timeline Find a path to another company

Partners 2

Strategic partnerships, joint products and alliances

MerckHealthcare · $290BBayer partnered with Arvinas on prostate cancer PROTAC
PfizerHealthcare · $160BPfizer $650M+ partnership on ARV-471 breast cancer PROTAC

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Arvinas's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=ARVN" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Arvinas on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.